#BEGIN_DRUGCARD DB01677

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
110-17-8

# ChEBI_ID:
29806

# Chemical_Formula:
C4H2O4

# Chemical_IUPAC_Name:
(2E)-but-2-enedioate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Solution	Respiratory (inhalation)

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.46

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
7000 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Fumarate

# HET_ID:
FMR

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/p-2/b2-1+

# InChI_Key:
InChIKey=VZCYOOQTPOCHFL-OWOJBTEDSA-L

# Indication:
Not Available

# KEGG_Compound_ID:
C00122

# KEGG_Drug_ID:
D02308

# LIMS_Drug_ID:
1677

# Mechanism_Of_Action:
Not Available

# Melting_Point:
287 dec °C

# Molecular_Weight_Avg:
114.0563

# Molecular_Weight_Mono:
113.995308552

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1D4E

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.02

# Predicted_LogS:
0.14

# Predicted_Water_Solubility:
2.06e+02 g/l

# Primary_Accession_No:
DB01677

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5460307

# PubChem_Substance_ID:
46508303

# RxList_Link:
http://www.rxlist.com/cgi/generic/perforomist.htm

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01460
EXPT01511

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[O-]C(=O)\C=C\C([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:23 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Fumarate

# pKa_Isoelectric_Point:
3.03 (at 18 °C)

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X89038

# Drug_Target_1_GenBank_ID_Protein:
1491644

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
mdh

# Drug_Target_1_Gene_Sequence:
>930 bp
ATGCGCAAGAAGATTAGTATTATCGGGGCAGGATTTGTCGGTTCGACGACAGCTCACTGG
CTGGCCGCTAAAGAATTAGGTGACATTGTTCTGCTTGATATTGTCGAGGGTGTGCCTCAA
GGCAAGGCTCTCGATCTCTACGAGGCATCACCAATTGAAGGGTTTGATGTTCGGGTGACC
GGCACGAACAACTACGCCGATACTGCCAACTCGGATGTCATCGTTGTTACGTCAGGTGCT
CCGCGCAAGCCGGGCATGAGCCGTGAGGATTTGATCAAGGTCAACGCCGACATCACCCGT
GCCTGTATCAGTCAGGCTGCCCCGCTCTCGCCGAATGCCGTGATTATCATGGTCAATAAT
CCTCTGGATGCGATGACCTATCTGGCGGCGGAGGTTAGTGGCTTCCCCAAAGAGCGTGTC
ATTGGTCAGGCCGGCGTCCTCGATGCGGCCCGCTATCGCACCTTCATTGCCATGGAGGCG
GGTGTTTCGGTTGAAGATGTTCAGGCGATGCTGATGGGTGGTCACGGCGATGAGATGGTA
CCGCTGCCCCGGTTTTCAACCATTAGCGGTATTCCGGTGAGCGAGTTCATTGCGCCTGAT
CGTCTGGCTCAGATTGTTGAGCGCACCCGGAAGGGTGGTGGCGAGATTGTGAATCTGCTG
AAGACCGGCAGTGCGTATTATGCTCCCGCCGCCGCCACAGCGCAGATGGTCGAAGCGGTG
CTCAAAGACAAGAAGCGGGTCATGCCGGTGGCAGCCTACCTGACCGGTCAGTACGGCCTG
AATGATATTTACTTTGGTGTACCGGTGATCCTCGGTGCCGGTGGAGTAGAGAAAATTCTC
GAATTGCCGCTCAACGAAGAGGAGATGGCACTGCTGAACGCATCGGCGAAAGCGGTACGT
GCCACCCTCGACACGCTGAAGTCTCTCTAA

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
3133356	Rolstad AK, Howland E, Sirevag R: Malate dehydrogenase from the thermophilic green bacterium Chloroflexus aurantiacus: purification, molecular weight, amino acid composition, and partial amino acid sequence. J Bacteriol. 1988 Jul;170(7):2947-53.
8661927	Synstad B, Emmerhoff O, Sirevag R: Malate dehydrogenase from the green gliding bacterium Chloroflexus aurantiacus is phylogenetically related to lactic dehydrogenases. Arch Microbiol. 1996 May;165(5):346-53.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2329

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
32717

# Drug_Target_1_Name:
Malate dehydrogenase

# Drug_Target_1_Number_of_Residues:
309

# Drug_Target_1_PDB_ID:
1UXG

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_1_Protein_Sequence:
>Malate dehydrogenase
MRKKISIIGAGFVGSTTAHWLAAKELGDIVLLDIVEGVPQGKALDLYEASPIEGFDVRVT
GTNNYADTANSDVIVVTSGAPRKPGMSREDLIKVNADITRACISQAAPLSPNAVIIMVNN
PLDAMTYLAAEVSGFPKERVIGQAGVLDAARYRTFIAMEAGVSVEDVQAMLMGGHGDEMV
PLPRFSTISGIPVSEFIAPDRLAQIVERTRKGGGEIVNLLKTGSAYYAPAAATAQMVEAV
LKDKKRVMPVAAYLTGQYGLNDIYFGVPVILGAGGVEKILELPLNEEEMALLNASAKAVR
ATLDTLKSL

# Drug_Target_1_Reaction:
(S)-malate + NAD+ = oxaloacetate + NADH + H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the reversible oxidation of malate to oxaloacetate

# Drug_Target_1_SwissProt_ID:
P80040

# Drug_Target_1_SwissProt_Name:
MDH_CHLAA

# Drug_Target_1_Synonyms:
EC 1.1.1.37

# Drug_Target_1_Theoretical_pI:
4.91

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Periplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AJ132010

# Drug_Target_2_GenBank_ID_Protein:
4539587

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
fccA

# Drug_Target_2_Gene_Sequence:
>1683 bp
AACCAAGAATGTGATAGCTGCCATACACCAGATGGTGAACTGTCAAATGACAGCTTAACT
TATGAAAATACACAATGTGTATCTTGCCATGGCACACTAGAGGAAGTCGCTGAAACGACA
AAACATGAACACTATAATGCTCATGCTTCTCATTTCCCTGGCGAAGTAGCTTGTACCTCA
TGCCACAGCGCACACGAAAAATCGATGGTGTATTGTGACTCTTGCCATAGCTTCGATTTC
AACATGCCTTATGCTAAAAAATGGCAACGTGACGAGCCTACTATTGCTGAACTGGCCAAA
GATAAATCAGAACGTCAGGCTGCTCTTGCTAGCGCACCTCACGATACTGTTGACGTAGTG
GTTGTCGGTTCTGGCGGCGCAGGTTTCTCAGCAGCAATATCTGCAACAGACAGTGGTGCT
AAAGTCATTCTTATTGAAAAAGAGCCTGTTATTGGTGGTAATGCTAAGTTAGCTGCGGGT
GGCATGAACGCTGCTTGGACTGATCAACAAAAAGCCAAAAAAATTACTGACAGCCCAGAG
TTAATGTTCGAAGACACCATGAAAGGTGGCCAAAACATAAATGATCCTGCATTAGTTAAA
GTATTAAGCTCACACTCTAAAGACTCTGTTGATTGGATGACCGCTATGGGTGCCGATTTA
ACTGATGTTGGCATGATGGGTGGCGCATCTGTTAATCGTGCGCATCGTCCAACCGGTGGT
GCTGGTGTAGGTGCTCATGTTGTTCAAGTACTTTATGATAATGCAGTGAAACGCAATATC
GACTTACGCATGAACACTCGCGGCATTGAAGTGCTTAAAGATGATAAAGGCACTGTTAAA
GGTATTCTGGTTAAGGGTATGTATAAAGGTTACTACTGGGTGAAAGCCGATGCGGTAATC
TTAGCAACGGGTGGTTTCGCTAAAAATAACGAGCGTGTCGCTAAGCTTGATCCTTCACTA
AAAGGCTTTATCTCTACTAACCAACCTGGTGCAGTAGGTGATGGACTGGATGTAGCGGAA
AATGCGGGCGGCGCATTGAAAGACATGCAGTATATCCAAGCTCACCCAACACTATCTGTT
AAAGGTGGCGTAATGGTCACTGAAGCGGTTCGTGGTAATGGTGCGATTTTGGTTAACCGT
GAAGGTAAGCGTTTCGTTAACGAAATTACTACTCGTGATAAAGCATCTGCCGCTATCTTA
GCGCAAACCGGTAAATCAGCTTATTTGATTTTTGATGATTCTGTGCGTAAGTCACTGTCA
AAAATTGATAAGTATATTGGTTTAGGTGTTGCACCAACCGCAGATAGCCTAGTTAAATTA
GGTAAAATGGAAGGTATTGACGGCAAAGCATTGACTGAAACTGTCGCGCGTTACAACAGC
TTAGTGAGTAGCGGTAAAGACACTGATTTTGAGCGTCCAAACCTACCGCGCGCACTTAAC
GAAGGTAACTACTATGCAATTGAAGTTACACCTGGTGTTCACCACACTATGGGTGGCGTG
ATGATCGACACTAAAGCTGAAGTCATGAATGCTAAGAAGCAGGTTATCCCTGGCTTGTAT
GGTGCTGGTGAGGTTACTGGCGGTGTTCATGGTGCTAACCGCTTAGGTGGTAATGCTATT
TCAGACATCATCACCTTCGGTCGCTTAGCGGGTGAAGAAGCTGCAAAATATTCTAAAAAG
AAC

# Drug_Target_2_General_Function:
Energy production and conversion

# Drug_Target_2_General_References:
10479620	Pealing SL, Lysek DA, Taylor P, Alexeev D, Reid GA, Chapman SK, Walkinshaw MD: Crystallization and preliminary X-ray analysis of flavocytochrome c(3), the fumarate reductase from Shewanella frigidimarina. J Struct Biol. 1999 Aug;127(1):76-8.
12093271	Pankhurst KL, Mowat CG, Miles CS, Leys D, Walkinshaw MD, Reid GA, Chapman SK: Role of His505 in the soluble fumarate reductase from Shewanella frigidimarina. Biochemistry. 2002 Jul 9;41(27):8551-6.
12356299	Mowat CG, Pankhurst KL, Miles CS, Leys D, Walkinshaw MD, Reid GA, Chapman SK: Engineering water to act as an active site acid catalyst in a soluble fumarate reductase. Biochemistry. 2002 Oct 8;41(40):11990-6.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3673

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
60622

# Drug_Target_2_Name:
Fumarate reductase flavoprotein subunit

# Drug_Target_2_Number_of_Residues:
571

# Drug_Target_2_PDB_ID:
1QJD

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00890	FAD_binding_2

# Drug_Target_2_Protein_Sequence:
>Fumarate reductase flavoprotein subunit
ADNLAEFHVQNQECDSCHTPDGELSNDSLTYENTQCVSCHGTLEEVAETTKHEHYNAHAS
HFPGEVACTSCHSAHEKSMVYCDSCHSFDFNMPYAKKWQRDEPTIAELAKDKSERQAALA
SAPHDTVDVVVVGSGGAGFSAAISATDSGAKVILIEKEPVIGGNAKLAAGGMNAAWTDQQ
KAKKITDSPELMFEDTMKGGQNINDPALVKVLSSHSKDSVDWMTAMGADLTDVGMMGGAS
VNRAHRPTGGAGVGAHVVQVLYDNAVKRNIDLRMNTRGIEVLKDDKGTVKGILVKGMYKG
YYWVKADAVILATGGFAKNNERVAKLDPSLKGFISTNQPGAVGDGLDVAENAGGALKDMQ
YIQAHPTLSVKGGVMVTEAVRGNGAILVNREGKRFVNEITTRDKASAAILAQTGKSAYLI
FDDSVRKSLSKIDKYIGLGVAPTADSLVKLGKMEGIDGKALTETVARYNSLVSSGKDTDF
ERPNLPRALNEGNYYAIEVTPGVHHTMGGVMIDTKAEVMNAKKQVIPGLYGAGEVTGGVH
GANRLGGNAISDIITFGRLAGEEAAKYSKKN

# Drug_Target_2_Reaction:
succinate + acceptor = fumarate + reduced acceptor

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown, but evidence indicates that flavocytochrome c participates in electron transfer from formate to fumarate and possibly also to trimethylamine oxide (TMAO). This enzyme is essentially unidirectional

# Drug_Target_2_SwissProt_ID:
P0C278

# Drug_Target_2_SwissProt_Name:
FRDA_SHEFR

# Drug_Target_2_Synonyms:
EC 1.3.99.1
Fcc3
Flavocytochrome c
Flavocytochrome c3

# Drug_Target_2_Theoretical_pI:
6.51

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Periplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AE014299

# Drug_Target_3_GenBank_ID_Protein:
24346572

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
SO_0970

# Drug_Target_3_Gene_Sequence:
>1791 bp
TTAATTATCTTTAGCGAATTTAGCGGCAGATGCACCCGCGATACGGCCGTAGGTGACGAT
ATCAGAGATAGCGTTACCACCTAAACGGTTAGCACCGTGAACACCACCAGTCACTTCGCC
TGCAGCGTATAAACCAGTGATAGGTTTACCGGTTTTCTCACTCTTCACTTCGGCTTTAGT
ATCAATCACCAGACCACCCATAGTGTGGTGAACCGCTGGTGCAATTTCTAAGGCGTAGAA
AGGAGCTACCACTAATTCACGTGGTAAATCAGGACGTTCAAATTGAGCATCTTTACCTGA
TTTAACGAAACCGTTGTAGGCTGTTACTGTTTTTGCCAATTCAGCTGCAGGTACATCGAT
TTGTTTCGCTAACTCTTCGATGGTTTTACCTTCTTTTACAATGTTCAGGTGAACATAACC
TTCGATGGCCTTCAAGCTCTTACGGATAGAGTCATCGAATACTAGGTAAGCGCTTTCACC
TTTTTGTTGCAGAATCGCCGCAGACGCTTTATCACGGGTGGTGATTTCGTTCATAAAACG
ATTACCTTCACGGTTCACCACGATTGCACCGTTACCACGTACTGCCTCGGTGATCATCAC
GCCACCCGCTGGAGAGTAAGTTGGGTGAGCTTGGATGTATTCTAAGTCACGTGTTGCTGC
GCCCGCTTGTAGAGCTACGTCTAAGCCGTCACCCGTCGCACCTGGGTGGTTGGTCGCTTT
AAAGCCTTTTAACTTAGGATCGTATTTAGAAACACGTTCGTTGTTTTTCGCAAAACCACC
TGCTGCAATGACTACTGCATCGGCTTTGATCACATAGTAACCTGTGTATTCACCTTTCAC
TAAAACGCCGGTCACTTTACCGCTTGCATCTTCAAGGATGCGCACAACGCGGCTGTTTAA
GCGAATATCAGTACCACGCTTAACGGCGTTGTCCCACAGCACTTGTGCTACGTGAGCACC
AACACCTGCACCACCGGTTGGACGGTGACTACGGTTAACGCTCGCGCCACCCATACGACC
CACGTCAGTCATGTCGGCACCCATAGAGGTTAACCAATCGATTGAGTCTGAAGAGTTGTT
AGCCAGTACTTTAACTAATTCAGGATCGTTGATGTTGCGGCCACCTTTCATAGTGTCGTC
GATCATGATTTGTTTCTTATCTTCGATACCTAACTTAGCCTGTGGCTTAGTTTCTGCGGC
GTTCATACCACCGGCAGCCAGTTTAGTGTTACCACCTGGGATAGGTTCTTTTTCTAACAG
AATCACTTTCGCGCCAGCATCACGGGCAGATACGGCAGCGGCAAGACCAGCACCACCAGA
GCCGATAATTACAACGTCTGTGGTTTCTTTCACACCAGCAGCAATGGCTTTATCTTGTGC
TGCTTTGTCTGCATCAACAGGTACAAACTTACGTTCCCACTTGCCACCAAATGGCATATC
GAAGCCGAAGCTATGGCAAGCATCACAATAAGCTACTGATTTTTCGTGGCCTTTGTGGCA
GCTCGTACAAGCGATTTCACCAATTAAGTGAGATTTGTGCGGAGAAACTTTATCTTTAGG
CGCTGCTGCAGCCAGTTCTTTTAAGTCACCGTGGCAGCTAACACATTGGCCATTCTCATG
GGTCAGGTTGTCGTTAGTCACGCCACCTTTGTCTGATACGTGGCAGCTATCGCAGCCACC
CATTTCACCGTGAAAATCGGCTAGTACTTCTGGAGCGGCATAGGCTGTGCCTGCCATTGC
GCCAGAGATCAGCATGGCTAGTGCTGTTTTTTGAATCTTTCTTGTGAACAT

# Drug_Target_3_General_Function:
Energy production and conversion

# Drug_Target_3_General_References:
10581551	Leys D, Tsapin AS, Nealson KH, Meyer TE, Cusanovich MA, Van Beeumen JJ: Structure and mechanism of the flavocytochrome c fumarate reductase of Shewanella putrefaciens MR-1. Nat Struct Biol. 1999 Dec;6(12):1113-7.
11425747	Tsapin AI, Vandenberghe I, Nealson KH, Scott JH, Meyer TE, Cusanovich MA, Harada E, Kaizu T, Akutsu H, Leys D, Van Beeumen JJ: Identification of a small tetraheme cytochrome c and a flavocytochrome c as two of the principal soluble cytochromes c in Shewanella oneidensis strain MR1. Appl Environ Microbiol. 2001 Jul;67(7):3236-44.
12368813	Heidelberg JF, Paulsen IT, Nelson KE, Gaidos EJ, Nelson WC, Read TD, Eisen JA, Seshadri R, Ward N, Methe B, Clayton RA, Meyer T, Tsapin A, Scott J, Beanan M, Brinkac L, Daugherty S, DeBoy RT, Dodson RJ, Durkin AS, Haft DH, Kolonay JF, Madupu R, Peterson JD, Umayam LA, White O, Wolf AM, Vamathevan J, Weidman J, Impraim M, Lee K, Berry K, Lee C, Mueller J, Khouri H, Gill J, Utterback TR, McDonald LA, Feldblyum TV, Smith HO, Venter JC, Nealson KH, Fraser CM: Genome sequence of the dissimilatory metal ion-reducing bacterium Shewanella oneidensis. Nat Biotechnol. 2002 Nov;20(11):1118-23. Epub 2002 Oct 7.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2709

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
62448

# Drug_Target_3_Name:
Fumarate reductase flavoprotein subunit

# Drug_Target_3_Number_of_Residues:
596

# Drug_Target_3_PDB_ID:
1D4C

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00890	FAD_binding_2

# Drug_Target_3_Protein_Sequence:
>Fumarate reductase flavoprotein subunit precursor
MFTRKIQKTALAMLISGAMAGTAYAAPEVLADFHGEMGGCDSCHVSDKGGVTNDNLTHEN
GQCVSCHGDLKELAAAAPKDKVSPHKSHLIGEIACTSCHKGHEKSVAYCDACHSFGFDMP
FGGKWERKFVPVDADKAAQDKAIAAGVKETTDVVIIGSGGAGLAAAVSARDAGAKVILLE
KEPIPGGNTKLAAGGMNAAETKPQAKLGIEDKKQIMIDDTMKGGRNINDPELVKVLANNS
SDSIDWLTSMGADMTDVGRMGGASVNRSHRPTGGAGVGAHVAQVLWDNAVKRGTDIRLNS
RVVRILEDASGKVTGVLVKGEYTGYYVIKADAVVIAAGGFAKNNERVSKYDPKLKGFKAT
NHPGATGDGLDVALQAGAATRDLEYIQAHPTYSPAGGVMITEAVRGNGAIVVNREGNRFM
NEITTRDKASAAILQQKGESAYLVFDDSIRKSLKAIEGYVHLNIVKEGKTIEELAKQIDV
PAAELAKTVTAYNGFVKSGKDAQFERPDLPRELVVAPFYALEIAPAVHHTMGGLVIDTKA
EVKSEKTGKPITGLYAAGEVTGGVHGANRLGGNAISDIVTYGRIAGASAAKFAKDN

# Drug_Target_3_Reaction:
succinate + acceptor = fumarate + reduced acceptor

# Drug_Target_3_Signals:
1-25

# Drug_Target_3_Specific_Function:
Catalyzes fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown, but evidence indicates that flavocytochrome c participates in electron transfer from formate to fumarate and possibly also to trimethylamine oxide (TMAO). This enzyme is essentially unidirectional

# Drug_Target_3_SwissProt_ID:
P83223

# Drug_Target_3_SwissProt_Name:
FRDA_SHEON

# Drug_Target_3_Synonyms:
EC 1.3.99.1
FL cyt
Flavocytochrome c
Fumarate reductase flavoprotein subunit precursor

# Drug_Target_3_Theoretical_pI:
7.64

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
ME2

# Drug_Target_4_GenBank_ID_Gene:
M55905

# Drug_Target_4_GenBank_ID_Protein:
187300

# Drug_Target_4_GeneCard_ID:
ME2

# Drug_Target_4_Gene_Name:
ME2

# Drug_Target_4_Gene_Sequence:
>1755 bp
ATGTTGTCCCGGTTAAGAGTAGTTTCCACCACTTGTACTTTGGCATGTCGACATTTGCAC
ATAAAAGAAAAAGGCAAGCCACTTATGCTGAACCCAAGAACAAACAAGGGAATGGCATTT
ACTTTACAAGAACGACAAATGCTTGGTCTTCAAGGACTTCTACCTCCCAAAATAGAGACA
CAAGATATTCAAGCCTTACGATTTCATAGAAACTTGAAGAAAATGACTAGCCCTTTGGAA
AAATATATCTACATAATGGGAATACAAGAAAGAAATGAGAAATTGTTTTATAGAATACTG
CAAGATGACATTGAGAGTTTAATGCCAATTGTATATACACCGACGGTTGGTCTTGCCTGC
TCCCAGTATGGACACATCTTTAGAAGACCTAAGGGATTATTTATTTCGATCTCAGACAGA
GGTCATGTTAGATCAATTGTGGATAACTGGCCAGAAAATCATGTTAAGGCTGTTGTAGTG
ACTGATGGAGAGAGAATTCTGGGTCTTGGAGATCTGGGTGTCTATGGAATGGGAATTCCA
GTAGGAAAACTTTGTTTGTATACAGCTTGTGCAGGAATACGGCCTGATAGATGCCTGCCA
GTGTGTATTGATGTGGGAACTGATAATATCGCACTCTTAAAAGACCCATTTTACATGGGC
TTGTACCAGAAACGAGATCGCACACAACAGTATGATGACCTGATTGATGAGTTTATGAAA
GCTATTACTGACAGATATGGCCGGAACACACTCATTCAGTTCGAAGACTTTGGAAATCAT
AATGCATTCAGGTTCTTGAGAAAGTACCGAGAAAAATATTGTACTTTCAATGATGATATT
CAAGGGACAGCTGCAGTAGCTCTAGCAGGTCTTCTTGCAGCACAAAAAGTTATTAGTAAA
CCAATCTCCGAACACAAAATCTTATTCCTTGGAGCAGGAGAGGCTGCTCTTGGAATTGCA
AATCTTATAGTTATGTCTATGGTAGAAAATGGCCTGTCAGAACAAGAGGCACAAAAGAAA
ATCTGGATGTTTGACAAGTATGGTTTATTAGTTAAGGGACGGAAAGCAAAAATAGATAGT
TATCAGGAACCATTTACTCACTCAGCCCCAGAGAGCATACCTGATACTTTTGAAGATGCA
GTGAATATACTGAAGCCTTCAACTATTATTGGAGTTGCAGGTGCTGGCCGTCTTTTCACT
CCTGATGTAATCAGAGCCATGGCCTCTATCAATGAAAGGCCTGTAATATTTGCATTAAGT
AATCCTACAGCACAGGCAGAGTGCACGGCTGAAGAAGCATATACACTTACAGAGGGCAGG
TGTTTGTTTGCCAGTGGCAGTCCATTTGGGCCAGTGAAACTTACAGATGGGCGAGTCTTT
ACACCAGGTCAAGGAAACAATGTTTATATTTTTCCAGGTGTGGCTTTAGCTGTTATTCTC
TGTAACACCCGGCATATTAGTGACAGTGTTTTCCTAGAAGCTGCAAAGGCCCTGACAAGC
CAATTGACAGATGAAGAGCTAGCCCAAGGGAGACTTTACCCACCGCTTGCTAATATTCAG
GAAGTTTCTATTAACATTGCTATTAAAGTTACAGAATACCTATATGCTAATAAAATGGCT
TTCCGATACCCAGAACCTGAAGACAAGGCCAAATATGTTAAAGAAAGAACATGGCGGAGT
GAATATGATTCCCTGCTGCCAGATGTGTATGAATGGCCAGAATCTGCATCAAGCCCTCCT
GTGATAACAGAATAG

# Drug_Target_4_General_Function:
Energy production and conversion

# Drug_Target_4_General_References:
11401430	Yanaihara N, Kohno T, Takakura S, Takei K, Otsuka A, Sunaga N, Takahashi M, Yamazaki M, Tashiro H, Fukuzumi Y, Fujimori Y, Hagiwara K, Tanaka T, Yokota J: Physical and transcriptional map of a 311-kb segment of chromosome 18q21, a candidate lung tumor suppressor locus. Genomics. 2001 Mar 1;72(2):169-79.
12121650	Yang Z, Lanks CW, Tong L: Molecular mechanism for the regulation of human mitochondrial NAD(P)+-dependent malic enzyme by ATP and fumarate. Structure. 2002 Jul;10(7):951-60.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
12962632	Tao X, Yang Z, Tong L: Crystal structures of substrate complexes of malic enzyme and insights into the catalytic mechanism. Structure. 2003 Sep;11(9):1141-50.
1993674	Loeber G, Infante AA, Maurer-Fogy I, Krystek E, Dworkin MB: Human NAD(+)-dependent mitochondrial malic enzyme. cDNA cloning, primary structure, and expression in Escherichia coli. J Biol Chem. 1991 Feb 15;266(5):3016-21.

# Drug_Target_4_HGNC_ID:
HGNC:6984

# Drug_Target_4_HPRD_ID:
01103

# Drug_Target_4_ID:
166

# Drug_Target_4_Locus:
6p25-p24|18q21

# Drug_Target_4_Molecular_Weight:
65444

# Drug_Target_4_Name:
NAD-dependent malic enzyme, mitochondrial

# Drug_Target_4_Number_of_Residues:
584

# Drug_Target_4_PDB_ID:
1QR6

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00390	malic
PF03949	Malic_M

# Drug_Target_4_Protein_Sequence:
>NAD-dependent malic enzyme, mitochondrial precursor
MLSRLRVVSTTCTLACRHLHIKEKGKPLMLNPRTNKGMAFTLQERQMLGLQGLLPPKIET
QDIQALRFHRNLKKMTSPLEKYIYIMGIQERNEKLFYRILQDDIESLMPIVYTPTVGLAC
SQYGHIFRRPKGLFISISDRGHVRSIVDNWPENHVKAVVVTDGERILGLGDLGVYGMGIP
VGKLCLYTACAGIRPDRCLPVCIDVGTDNIALLKDPFYMGLYQKRDRTQQYDDLIDEFMK
AITDRYGRNTLIQFEDFGNHNAFRFLRKYREKYCTFNDDIQGTAAVALAGLLAAQKVISK
PISEHKILFLGAGEAALGIANLIVMSMVENGLSEQEAQKKIWMFDKYGLLVKGRKAKIDS
YQEPFTHSAPESIPDTFEDAVNILKPSTIIGVAGAGRLFTPDVIRAMASINERPVIFALS
NPTAQAECTAEEAYTLTEGRCLFASGSPFGPVKLTDGRVFTPGQGNNVYIFPGVALAVIL
CNTRHISDSVFLEAAKALTSQLTDEELAQGRLYPPLANIQEVSINIAIKVTEYLYANKMA
FRYPEPEDKAKYVKERTWRSEYDSLLPDVYEWPESASSPPVITE

# Drug_Target_4_Reaction:
(S)-malate + NAD+ = pyruvate + CO2 + NADH

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
P23368

# Drug_Target_4_SwissProt_Name:
MAOM_HUMAN

# Drug_Target_4_Synonyms:
EC 1.1.1.38
Malic enzyme 2
NAD-ME
NAD-dependent malic enzyme, mitochondrial precursor

# Drug_Target_4_Theoretical_pI:
7.67

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
Not Available

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
FAH

# Drug_Target_5_Gene_Sequence:
Not Available

# Drug_Target_5_General_Function:
Not Available

# Drug_Target_5_General_References:
Not Available

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
7041

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
Not Available

# Drug_Target_5_Name:
Fumarylacetoacetase

# Drug_Target_5_Number_of_Residues:
0

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
Not Available

# Drug_Target_5_Protein_Sequence:
Not Available

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
Not Available

# Drug_Target_5_Specific_Function:
Not Available

# Drug_Target_5_SwissProt_ID:
P16930

# Drug_Target_5_SwissProt_Name:
FAAA_HUMAN

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
Not Available

# Drug_Target_5_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB01677
